Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells

被引:307
作者
Fujita, Yasunori [1 ]
Kojima, Keitaro [2 ]
Hamada, Nanako [1 ]
Ohhashi, Riyako [1 ]
Akao, Yukihiro [1 ]
Nozawa, Yoshinori [1 ]
Deguchi, Takashi [2 ]
Ito, Masafumi [1 ]
机构
[1] Gifu Int Inst Biotechnol, Dept Longev & Aging Res, Gifu 5040838, Japan
[2] Gifu Univ, Grad Sch Med, Dept Urol, Gifu 5011193, Japan
关键词
microRNA; miR-34a; p53; SIRT1; Prostate cancel; PC3; Androgen-refractory; Cell cycle arrest; Camptothecin; Chemoresistance;
D O I
10.1016/j.bbrc.2008.09.086
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Tumor suppressor p53 transcriptionally regulates expression of microRNA-34a, which confers translational inhibition and mRNA degradation of genes involved in cell cycle control and apoptosis. in Various cancers. miR-34a expression is lost or reduced. Here, we investigated the role of miR-34a in prostate cancer cell lines. MiR-34a expression was markedly reduced in p53-null PC3 cells and p53-mutated DU145 cells compared with LNCaP cells expressing wild-type p53. In PC3 cell, ectopic expression of miR-34a decreased the SIRT1 mRNA and protein levels as well as protein levels of known direct tat-get genes. Reporter assays revealed that miR-34a-induced SIRT1 inhibition occurred at the transcriptional but not post-transcriptional level despite the presence of a potential miR-34a binding site within its 3'-UTR. Ectopic miR-34a expression resulted in cell cycle arrest and growth inhibition and attenuated chemoresistance to anticancer drug camptothecin by inducing apoptosis, suggesting a potential role of miR-34a for the treatment of p53-defective prostate cancer. (C) 2008 Elsevier Inc. All rights reserved.
引用
收藏
页码:114 / 119
页数:6
相关论文
共 16 条
  • [1] Genomic profiling of MicroRNA and messenger RNA reveals deregulated MicroRNA expression in prostate cancer
    Ambs, Stefan
    Prueitt, Robyn L.
    Yi, Ming
    Hudson, Robert S.
    Howe, Tiffany M.
    Petrocca, Fabio
    Wallace, Tiffany A.
    Liu, Chang-Gong
    Volinia, Stefano
    Calin, George A.
    Yfantis, Harris G.
    Stephens, Robert M.
    Croce, Carlo M.
    [J]. CANCER RESEARCH, 2008, 68 (15) : 6162 - 6170
  • [2] MicroRNA signatures in human cancers
    Calin, George A.
    Croce, Carlo M.
    [J]. NATURE REVIEWS CANCER, 2006, 6 (11) : 857 - 866
  • [3] Control of multidrug resistance gene mdr1 and cancer resistance to chemotherapy by the longevity gene sirt1
    Chu, F
    Chou, PM
    Zheng, X
    Mirkin, BL
    Rebbaa, A
    [J]. CANCER RESEARCH, 2005, 65 (22) : 10183 - 10187
  • [4] Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight?
    Filipowicz, Witold
    Bhattacharyya, Suvendra N.
    Sonenberg, Nahum
    [J]. NATURE REVIEWS GENETICS, 2008, 9 (02) : 102 - 114
  • [5] ALTERATION OF THE TUMOR-SUPPRESSOR GENE P53 IN A HIGH FRACTION OF HORMONE-REFRACTORY PROSTATE-CANCER
    HEIDENBERG, HB
    SESTERHENN, IA
    GADDIPATI, JP
    WEGHORST, CM
    BUZARD, GS
    MOUL, JW
    SRIVASTAVA, S
    [J]. JOURNAL OF UROLOGY, 1995, 154 (02) : 414 - 421
  • [6] p53 enters the MicroRNA world
    Hermeking, Heiko
    [J]. CANCER CELL, 2007, 12 (05) : 414 - 418
  • [7] P53 MUTATIONS IN HUMAN CANCERS
    HOLLSTEIN, M
    SIDRANSKY, D
    VOGELSTEIN, B
    HARRIS, CC
    [J]. SCIENCE, 1991, 253 (5015) : 49 - 53
  • [8] ISAACS WB, 1991, CANCER RES, V51, P4716
  • [9] AUTOREGULATORY CONTROL OF E2F1 EXPRESSION IN RESPONSE TO POSITIVE AND NEGATIVE REGULATORS OF CELL-CYCLE PROGRESSION
    JOHNSON, DG
    OHTANI, K
    NEVINS, JR
    [J]. GENES & DEVELOPMENT, 1994, 8 (13) : 1514 - 1525
  • [10] A role for SIRT1 in cell growth and chemoresistance in prostate cancer PC3 and DU145 cells
    Kojima, Keitaro
    Ohhashi, Riyako
    Fujita, Yasunori
    Hamada, Nanako
    Akao, Yukihiro
    Nozawa, Yoshinori
    Deguchi, Takashi
    Ito, Masafumi
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2008, 373 (03) : 423 - 428